Original Publication Date: 1 January, 2016
Publication / Source: Immunotherapy
Authors: Masanori Noguchi, Noriko Koga, Fukuko Moriya & Kyogo Itoh
Although treatment options for castration-resistant prostate cancer (CRPC) have increased over the last decade, there remains a need for strategies that can provide durable disease control and long-term benefit. Recently, immunotherapy has emerged as a viable and attractive strategy for the treatment of CRPC. To date, there are multiple strategies to target the immune system, and several approaches including therapeutic cancer vaccines and immune checkpoint inhibitors have been most successful in clinical trials.